Research News

New research from the University of Eastern Finland sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by limiting the activity of coregulator proteins.

Infection with the influenza virus leads to lung injury through inflammation over-activation that causes collateral damage to cells required for breathing. Such damage can be life-threatening, but scientists have a new preventative treatment. A team from St. Jude Children’s Research Hospital, University of Houston, Tufts University School of Medicine and Fox Chase Cancer Center created a drug that can prevent flu-induced lung injury.

Acertain variant of a key anti-inflammatory gene protects men under age 75 from severe illness and death when hospitalized from COVID-19, a genetic analysis of their blood shows.

Scientists at Uppsala University have discovered a new class of antibiotics with potent activity against multi-drug resistant bacteria, and have shown that it cures bloodstream infections in mice. The new antibiotic class is described in an article in the scientific journal PNAS.

The President of India Smt. Droupadi Murmu launched India’s first home-grown anti-Cancer CAR-T cell therapy and dedicated it to the Nation in the presence of the Governor of Maharashtra, Shri Ramesh Bais at the Indian Institute of Technology, (IIT) Bombay in Mumbai today. Also present on the occasion were Director, IIT Bombay, Prof. Subhasis Chaudhuri and Director, Tata Memorial Centre, Prof. Sudeep Gupta along with the key contributors including Prof. Rahul Purwar, Department of Bioscience and Bioengineering, IIT Bombay, and Dr. Hasmukh Jain and Dr.

Scientists at King’s have discovered a new cause for asthma that sparks hope for treatment that could prevent the life-threatening disease.

Bariatric surgery may result in significant cardiometabolic improvements, particularly among younger, female, or white people and those without comorbidities, according to new research published in the Journal of the Endocrine Society.

A woman’s cardiovascular risk can rise sharply after she goes through menopause, quickly catching up to men of a similar age and health profile, according to new findings presented at the American College of Cardiology’s Annual Scientific Session. Researchers said the study underscores the importance of recognizing and addressing early warning signs of heart disease risk in women as they lose the protective effects of estrogen after menopause.

Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT.